Colloid Carcinoma of Pancreas in the Setting of Intraductal Papillary Mucinous Neoplasm (IPMN)

Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

Conclusions Multiple KRAS mutations along with TP53 mutation are genetic markers for C-PDC, which could be detected using pancreatic juice preoperatively.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
AbstractProgress in diagnostic modalities, surgical procedures, and multidisciplinary treatment for pancreatic diseases has increased the number of long-term survivors after pancreatic resection. Several reports have focused on high-risk lesions (HRLs), including high-grade pancreatic intraepithelial neoplasia (PanIN), pancreatic ductal adenocarcinoma, high-grade intraductal papillary mucinous neoplasm (IPMN), and IPMN with an associated invasive carcinoma, in the remnant pancreas after partial pancreatic resection for pancreatic cancer or IPMN. The etiology of HRLs in the remnant pancreas is thought to be either isolated ...
Source: Surgery Today - Category: Surgery Source Type: research
Authors: Ivry SL, Knudsen GM, Caiazza F, Sharib JM, Jaradeh K, Ravalin M, O'Donoghue AJ, Kirkwood KS, Craik CS Abstract Incidental detection of pancreatic cysts has increased dramatically over the last decade, but risk stratification and clinical management remain a challenge. Mucinous cysts are precursor lesions to pancreatic cancer, however, the majority are indolent. Current diagnostics cannot identify mucinous cysts that harbor cancer or reliably differentiate these lesions from nonmucinous cysts, which present minimal risk of malignant progression. We previously determined that activity of two aspartyl proteas...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
Significantly amplified regions (red) and significantly deleted regions (green) by patient and by the histologic grade of IPMNs are shown. The 7q21 amplification and 8q24 amplification (MYC) showed significant association with invasive carcinoma of IPMN. AbstractIntraductal papillary mucinous neoplasm (IPMN) of pancreas has a high risk to develop into invasive cancer or co ‐occur with malignant lesion. Therefore, it is important to assess its malignant risk by less‐invasive approach. Pancreatic juice cell‐free DNA (PJD) would be an ideal material in this purpose, but genetic biomarkers for predicting malignant risk f...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusions The study systematically summarizes characteristics and behaviors of primary pancreatic cancer by histological subtypes, which can facilitate the management of pancreatic cancer.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Conclusions Neutrophil-to-lymphocyte ratio was significantly higher in patients with IPMN-associated invasive carcinoma as compared with patients with noninvasive disease; however, NLR was not helpful in differentiating between high- and low-grade lesions.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Abstract Intraductal papillary mucinous neoplasms (IPMNs) are cystic neoplasms with the potential for progression to pancreatic cancer. Accurate prediction of the malignant potential is challenging and a proper treatment strategy has not been well established. Preoperative neutrophil-to-lymphocyte ratio (NLR) is a biomarker of the malignant potential in patients with several types of malignancy. We explored malignant potential in patients with IPMN. The present study included 56 patients aged of 73 ± 9 years (mean ± standard deviation) who underwent curative resection for IPMN fr...
Source: Biomarker Insights - Category: General Medicine Authors: Tags: Biomark Insights Source Type: research
AbstractIntraductal papillary mucinous neoplasms (IPMN) of the pancreas are premalignant mucin-producing epithelial tumors that arise from the pancreatic ductal system. These cystic tumors represent 15 –30% of cystic lesions of the pancreas [Basturk et al. in Am J Surg Pathol 39(12):1730–1741,1; Ferrone et al. in Arch Surg (Chicago, Ill: 1960) 144(5):448 –454,2, Kosmahl et al. in Virchows Arch Int J Pathol 445(2):168 –178,3; Spinelli et al. in Ann Surg. 239(5):651 –657,4]. It is believed that IPMN can progress from low-grade dysplasia to high-grade dysplasia to invasive cancer, and this pathwa...
Source: Updates in Surgery - Category: Surgery Source Type: research
Abstract OBJECTIVE: To study the relationship between the expression of SATB2 in colonic adenocarcinoma and clinicopathological factors, and its role in the identification of ovarian digestive system metastatic adenocarcinoma. METHODS: Immunohistochemistry was used to analyze the expression of SATB2 in 130 cases of colon adenocarcinoma, 46 cases of gastric adenocarcinoma, 47 cases of pancreatic ductal adenocarcinoma, 22 cases of cholangiocarcinoma, 53 cases of ovarian mucinous adenocarcinoma, and 38 cases of ovarian metastasis of colorectal carcinoma. Data was analyzed using SPSS 16.0 statistical software. ...
Source: Pathology, Research and Practice - Category: Pathology Authors: Tags: Pathol Res Pract Source Type: research
In this study, all tumors were adenocarcinomas that originate from ducts or ductules but infiltrate to involve all components of the pancreas. Other tumors that originate in pancreas may have different properties and a future study of in situ tumor is likely needed to determine whether the tumor tissue retains a structural remnant of its originating tissue. Methods and Materials Histology Sample Preparation Samples of normal human pancreas from five patients and pancreatic ductal adenocarcinoma tissue samples from ten patients were obtained with informed consent and institutional approval (University Health Network Toro...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Mucinous Carcinoma | Pancreas | Pancreatic Cancer